Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Lymphoma, Mantle-Cell × umbralisib × Clear all

Phase

Phase 1 2 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1

Interventions

Rituximab 34 Cyclophosphamide 22 Peripheral Blood Stem Cell Transplantation 15 Lenalidomide 11 fludarabine phosphate 10 Etoposide 9 Bortezomib 9 ibrutinib 8 Filgrastim 8 fludarabine 7 Vincristine 7 Mycophenolic Acid 7 Melphalan 7 Cytarabine 7 Cyclosporine 7 Bendamustine Hydrochloride 7 venetoclax 6 Whole-Body Irradiation 6 Methotrexate 6 acalabrutinib 5 Doxorubicin 5 Carboplatin 5 CT-P10 5 obinutuzumab 4 Radiotherapy 4 Prednisone 4 Ifosfamide 4 Everolimus 4 Dexamethasone 4 Carmustine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04692155 2023-09-28

CHOP U2

University of Alabama at Birmingham

Phase 1/2 Terminated

1 enrolled 5 charts

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡